Stoke Therapeutics names Thomas McCauley chief scientific officer

Stoke Therapeutics has appointed Thomas McCauley as its new Chief Scientific Officer. In this role, he will lead the company's scientific strategy, pipeline expansion, and execution across its RNA medicines platform. McCauley brings extensive experience, having previously served as President and CEO of Neptune Bio and held CSO positions at Omega Therapeutics, Macrolide Pharmaceuticals, and Translate Bio.

Stoke Therapeutics appointed Thomas McCauley as chief scientific officer to lead scientific strategy, pipeline expansion, and execution across its RNA medicines platform. * McCauley most recently served as president and CEO of Neptune Bio. * He previously held chief scientific officer roles at Omega Therapeutics, Macrolide Pharmaceuticals, and Translate Bio. * Stoke’s lead investigational medicine, zorevunersen, remains in development as a potential disease-modifying treatment for Dravet syndrome. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130730BIZWIRE_USPR_____20260713_BW413645) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Stoke Therapeutics appointed Thomas McCauley as chief scientific officer to lead scientific strategy, pipeline expansion, and execution across its RNA medicines platform. * McCauley most recently served as president and CEO of Neptune Bio. * He previously held chief scientific officer roles at Omega Therapeutics, Macrolide Pharmaceuticals, and Translate Bio. * Stoke’s lead investigational medicine, zorevunersen, remains in development as a potential disease-modifying treatment for Dravet syndrome. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130730BIZWIRE_USPR_____20260713_BW413645) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)